1. Immobilized Anti-CEA Antibody at 2 μg/mL (100 μL/well) can bind Recombinant Human CEACAM5/CD66e Protein (His Tag), the EC50 is 5.5-16 ng/mL.
2. Loaded Anti-Human CEACAM5 antibody, human IgG1 on ProA Biosensor, can bind Recombinant Human CEACAM5 Protein, His Tag with an affinity constant of 3.72 nM as determined in a BLI assay (Routinely tested).

CEACAM5 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 72.8 kDa and the accession number is A0A024R0K5.

Human

HEK293 Cells

CEA,CD66e,carcinoembryonic antigen-related cell adhesion molecule 5

A DNA sequence encoding the mature form of human CEACAM5 (NP_004354.2) (Met 1-Ala 685) was fused with a polyhistidine tag at the C-terminus. Predicted N terminal: Lys 35

≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

Reconstituted with sterile deionized water to 0.25 mg/mL. Reconstitution conditions may vary depending on the lot.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

CEACAM5, also known as CEA or D66e, belongs to the large CEACAM subfamily of the immunoglobulin superfamily. CEACAM5 is expressed primarily by epithelial cells, and is synthesized as a glycoprotein with an MW of 180 kDa comprising 60% carbohydrate. CEACAM5 contains one Ig-like V-type domain at the N-terminus, followed by six Ig-like C2-type domains and a GPI anchor, and exists as a homodimer. CEACAM5 and CEACAM6 are overexpressed in many cancers and are associated with adhesion and invasion. CEACAM5 can mediate cell-cell adhesion through homotypic and heterotypic interactions. It functions as a homotypic intercellular adhesion molecule and serves as a widely used tumor marker, since it is expressed at higher levels in tumorous tissues than in corresponding normal tissues. CEACAM5 has also been shown to contribute to tumorigenicity by inhibiting cellular differentiation. In addition, CEACAM5 is identified as the host receptor for the Dr family of adhesins of E.Coli, and the binding of E.coli Dr adhesins leads to dissociation of the CEACAM5 homodimer.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy